FDA Drug Approvals
Printable Version   Email to a friend

Kepivance Amgen Inc. - Treatment for Severe Oral Mucositis in Cancer Patients

Kepivance is a recombinant human keratinocyte growth factor indicated to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients with hematologic (blood) cancers undergoing high-dose chemotherapy, with or without radiation, followed by a bone marrow transplant.

Related Articles:

Amgen Submits Biologics License Application for FDA Approval of Palifermin - June 24, 2004

Latest FDA Drug Approvals...

FDA Drug Approvals Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec

More News Resources


MedNotes
Advertisement